Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs.
Rassnick
Kenneth M
KM
Department of Clinical Sciences, Cornell University, College of Veterinary Medicine, Box 31, Ithaca, NY 14853, USA. kmr32@cornell.edu
Muindi
Josephia R
JR
Johnson
Candace S
CS
Bailey
Dennis B
DB
Trump
Donald L
DL
D000284:Administration, Oral; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001682:Biological Availability; D002117:Calcitriol / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002945:Cisplatin / Q000008:administration & dosage; D018592:Cross-Over Studies; D004283:Dog Diseases; D004285:Dogs; D004334:Drug Administration Schedule; D004342:Drug Hypersensitivity / Q000209:etiology*; D006207:Half-Life; D007262:Infusions, Intravenous; D020714:Maximum Tolerated Dose; D009369:Neoplasms / Q000188:drug therapy* / Q000662:veterinary; D011863:Radioimmunoassay; D011897:Random Allocation
D002117:Calcitriol; D002945:Cisplatin